Greylock XII’s Rhythm Pharmaceuticals RYTM Stock Holding History

Greylock XII’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-54,749	Closed	-$1.6M	–	4
2018 Q3	$1.6M	Buy	+54,749	New	+$1.73M	1.12%	4

Other funds holding RYTM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Greylock XII's RYTM Position: Q4 2018 in Review

Greylock XII sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2018, closing a stake of 54,749 shares — an estimated $1.6M sold.

Greylock XII first reported a position in RYTM in Q3 2018 and held it in 1 quarter. The position peaked at $1.6M in Q3 2018. 74 funds tracked by Wall St. Rank hold RYTM as of Q4 2018.

Greylock XII reported no remaining Rhythm Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Greylock XII sold 54,749 Rhythm Pharmaceuticals shares in Q4 2018, an estimated $1.6M.
Greylock XII first reported a position in Rhythm Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Greylock XII's Rhythm Pharmaceuticals position peaked at $1.6M in Q3 2018.
74 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2018.

Based on Greylock XII's 13F filing for Q4 2018, filed 1 May 2019.